Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) View Full Press Release Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit Travere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results